# DreaMed Diabetes

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dreamed-diabetes

- Industry: Medical Devices & Equipment
- Headquarters: Petah Tikva, Israel
- Website: www.dreamed.ai/
- Total disclosed funding: $3M
- Latest round: Series B (Aug 19, 2024)
- Investors on record: 1

## About

Based in Petah Tikva, Israel, and founded in 2014 by Chief Executive Officer Eran Atlas and co-founder Ido Mueller, DreaMed Diabetes, Ltd. operates as a health tech company developing solutions for treating diabetes that utilizes event-driven machine learning and logic technologies. In August 2024, DreaMed Diabetes, Ltd. raised USD 3 million in Series B funding led by eHealth Ventures.

DreaMed Diabetes, Ltd. focuses on creating diabetes management through artificial intelligence (AI). The company developed a product known as Endo. Digital, which is a cloud-based platform that supports healthcare providers by offering AI-powered treatment recommendations for both Type 1 and Type 2 diabetes. Its system integrates with electronic medical records (EMR), automates billing documentation, and engages patients through a mobile app. In addition, the firm leverages technology-based tools for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps.

The company plans to use the funding from August 2024 to expand operations in the U.S., advance its platform, and grow the team. The funds will support scaling efforts, enhance technology, and drive new partnerships, including recent agreements with Abbott and Yale New Haven Health.

## Funding rounds

- Series B, Aug 19, 2024, $3M — eHealth Ventures

## Investors

- eHealth Ventures (https://capitalatlas.ai/funds/ehealth-ventures) — Series B